Biotechnolgy firm Precision BioSciences  is suing Cellectis SA in a dispute over a patent covering genome editing technology.

The suit was filed in the U.S. District Court for the Eastern District of North Carolina.

“Cellectis’ continued disregard for Precision’s foundational gene editing patent estate will not be tolerated,” said Matthew Kane, CEO of Precision BioSciences, in a statement. “Precision expects all competitors, domestic and foreign, to obey United States law and to refrain from illegal use of our proprietary technology.”

Precision is seeking monetary damages and a permanent injunction in use of the disputed technology.